Detalles de la búsqueda
1.
Establishing Meaningful Change Thresholds in Patient-Reported Outcomes Among Patients With Anaplastic Lymphoma Kinase-Positive Non-Small Cell Lung Cancer in ALTA-1L Trial.
Value Health
; 27(2): 182-189, 2024 Feb.
Artículo
en Inglés
| MEDLINE | ID: mdl-37951539
2.
Real-world evidence in lung and hematologic oncology health technology appraisals: a review of six assessment agencies.
Future Oncol
; 19(8): 603-616, 2023 Mar.
Artículo
en Inglés
| MEDLINE | ID: mdl-37083358
3.
Economic burden in patients with anaplastic lymphoma kinase (ALK)-positive non-small cell lung cancer (NSCLC), with or without brain metastases, receiving first-line ALK inhibitors.
J Oncol Pharm Pract
; 29(6): 1418-1427, 2023 Sep.
Artículo
en Inglés
| MEDLINE | ID: mdl-36131505
4.
Real-World Efficacy and Tolerability of Brigatinib in Patients with Non-Small Cell Lung Cancer with Prior ALK-TKIs in the United States.
Oncologist
; 27(9): 790-798, 2022 09 02.
Artículo
en Inglés
| MEDLINE | ID: mdl-35781589
5.
Indirect comparisons of brigatinib and alectinib for front-line ALK-positive non-small-cell lung cancer.
Future Oncol
; 18(20): 2499-2510, 2022 Jun.
Artículo
en Inglés
| MEDLINE | ID: mdl-35608148
6.
Real-World Treatment Patterns and Progression-Free Survival Associated with Anaplastic Lymphoma Kinase (ALK) Tyrosine Kinase Inhibitor Therapies for ALK+ Non-Small Cell Lung Cancer.
Oncologist
; 25(10): 867-877, 2020 10.
Artículo
en Inglés
| MEDLINE | ID: mdl-32490560
7.
Real-world treatment duration in ALK-positive non-small-cell lung cancer patients receiving brigatinib through the early access program.
Future Oncol
; 16(15): 1031-1041, 2020 May.
Artículo
en Inglés
| MEDLINE | ID: mdl-32338548
8.
A Low Temperature Drifting Acoustic Wave Pressure Sensor with an Integrated Vacuum Cavity for Absolute Pressure Sensing.
Sensors (Basel)
; 20(6)2020 Mar 24.
Artículo
en Inglés
| MEDLINE | ID: mdl-32213862
9.
Patient-reported outcomes and quality of life in advanced ALK+ non-small-cell lung cancer trial of brigatinib (ALTA).
Future Oncol
; 15(24): 2841-2855, 2019 Aug.
Artículo
en Inglés
| MEDLINE | ID: mdl-31364872
10.
Patient-reported health-related quality of life from the phase III TOURMALINE-MM1 study of ixazomib-lenalidomide-dexamethasone versus placebo-lenalidomide-dexamethasone in relapsed/refractory multiple myeloma.
Am J Hematol
; 2018 May 04.
Artículo
en Inglés
| MEDLINE | ID: mdl-29726031
11.
Demonstration of 10 nm Ferroelectric Al0.7Sc0.3N-Based Capacitors for Enabling Selector-Free Memory Array.
Materials (Basel)
; 17(3)2024 Jan 27.
Artículo
en Inglés
| MEDLINE | ID: mdl-38591456
12.
Efficacy of Mobocertinib and Amivantamab in Patients With Advanced Non-Small Cell Lung Cancer With EGFR Exon 20 Insertions Previously Treated With Platinum-Based Chemotherapy: An Indirect Treatment Comparison.
Clin Lung Cancer
; 25(3): e145-e152.e3, 2024 May.
Artículo
en Inglés
| MEDLINE | ID: mdl-38114357
13.
Identifying symptomatic adverse events using the patient-reported outcomes version of the common terminology criteria for adverse events in patients with non-small cell lung cancer with epidermal growth factor receptor exon 20 insertion mutations.
Cancer Med
; 12(5): 5494-5505, 2023 03.
Artículo
en Inglés
| MEDLINE | ID: mdl-36583557
14.
Real-world ALK Testing Trends in Patients With Advanced Non-Small-Cell Lung Cancer in the United States.
Clin Lung Cancer
; 24(1): e39-e49, 2023 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-36376172
15.
Real-World Response and Outcomes in Patients With NSCLC With EGFR Exon 20 Insertion Mutations.
JTO Clin Res Rep
; 4(10): 100558, 2023 Oct.
Artículo
en Inglés
| MEDLINE | ID: mdl-37744306
16.
Distribution and Detectability of EGFR Exon 20 Insertion Variants in NSCLC.
J Thorac Oncol
; 18(6): 744-754, 2023 06.
Artículo
en Inglés
| MEDLINE | ID: mdl-36738930
17.
Brigatinib Versus Alectinib in ALK-Positive NSCLC After Disease Progression on Crizotinib: Results of Phase 3 ALTA-3 Trial.
J Thorac Oncol
; 18(12): 1743-1755, 2023 12.
Artículo
en Inglés
| MEDLINE | ID: mdl-37574132
18.
Comparative effectiveness of mobocertinib and standard of care in patients with NSCLC with EGFR exon 20 insertion mutations: An indirect comparison.
Lung Cancer
; 179: 107186, 2023 05.
Artículo
en Inglés
| MEDLINE | ID: mdl-37075617
19.
Indirect comparison of mobocertinib and real-world therapies for pre-treated non-small cell lung cancer with EGFR exon 20 insertion mutations.
Lung Cancer
; 179: 107191, 2023 05.
Artículo
en Inglés
| MEDLINE | ID: mdl-37058788
20.
EGFR Testing Patterns and Detection of EGFR Exon 20 Insertions in the United States.
JTO Clin Res Rep
; 3(3): 100285, 2022 Mar.
Artículo
en Inglés
| MEDLINE | ID: mdl-35199057